Proteus mirabilis, FK041 had good activity comparable or superior to those of CFDNand CDTR. However, it was inferior to CDTRin activity against Moraxella catarrhalis, Haemophilus influenzae, Morganella morganii, and Serratia marcescens, and was inactive against Pseudomonas aeruginosa. With FK041 a small difference between MICand MBCagainst S. aureus, E. coli, K. pneumoniae, and H. influenzae was found, indicating that its action is bactericidal against these species. FK041 was stable to group 2 /3-lactamase hydrolysis but was unstable to group 1 /3-lactamase hydrolysis. The stability of FK041 to these enzymes was similar to those of CFDNand CDTR.FK041 showed high affinity for the main penicillin-binding proteins (PBPs) ofS. aureus (PBP 3, 2, and 1) and£. coli (PBP 3, 4, lbs, 2, and la).
In the past 30 years, various orally active cephem antibiotics have been developed with the aim of improving antibacterial potency and oral absorbability1~3). The clinical usefulness of oral oaminocephems was limited, however, because of their relatively low activity against Gram-negative bacilli. In order to overcome this defect, new oral cephalosporins such as cefixime (CFIX)4) and cefteram5) with potent activity against Gram-negative bacteria and good stability to /3-lactamase hydrolysis from
Gram-negative bacteria were developed in the early 1980s. Although these compoundshad advantages in their spectrum of activity against Gram-negative bacteria, the activity against staphylococci was not satisfactory. In 1988, we reported cefdinir (CFDN) with potent activity against Gram-positive bacteria, while maintaining the antibacterial spectrum of CFIX against Gram-negative strains6~8).
Werecently found a new orally active cephalosporin, FK041, in the course of screening for more potent activity and higher oral absorption9 '10) . In order to define clearly the antibacterial activity of FK041, a comprehensive in vitro evaluation of antibacterial activity was undertaken. 
Materials and Methods
Antibiotic s FK04 1 , CFDN, and cefditoren (CDTR) were synthesized in the Medicinal Chemistry Research Laboratories, Fujisawa Pharm. Co., Ltd., Osaka, Japan.
Bacterial Strains
Reference strains from the culture collection in our laboratories were used in this study. Clinical isolates of various species of bacteria were obtained from several hospitals in Japan. The criteria for drug resistance were MICs of^12.5^g/ml of methicillin for methicillin-resistant exhibited more potent activity than CDTRagainst S. aureus and enterococci, however, it was less active against S. pyogenes S. mitis and S. mutans. The activity of FK041 was similar or superior to that of CDTR against most Gram-negative bacteria, except that it was less active (Table 2) show that FK041 has potent and broad activity and that its activity is similar or superior to those of CFDNand CDTR against most anaerobic organisms tested except Clostridium perfringens. The activities of FK041against various clinical isolates were compared with those of CFDNand CDTR. Table 3 shows the drug concentration necessary to inhibit 50% Proteus mirabilis (2) (levofloxacin:^3. 13^g/ml) that of CDTR. FK041 exhibited good MIC5Os, which were lower than those of CFDNand CDTR, but poor MIC90s against Citrobacter freundii and Enterobacter cloacae. The compound, however, was inferior to CDTR in activity against Moraxella catarrhalis, H. influenzae, Morganella morganii, and Serratia marcescens and was inactive against Pseudomonasaeruginosa. Its activity against Bacteroides fragilis was slightly weaker than that of CDTRbut stronger than that of CFDN.
Antibacterial Activity of FK04 1 against /3-Lactam-resistant and Fluoroquinolone-resistant Organisms Antibacterial activities of FK041 and reference compounds 655 against /3-lactam-resistant and fluoroquinolone-resistant organisms are shown in Table 4 . FK041 was inactive against MRSAand MRSE like CFDN and CDTR. FK041 showed fairly good activity against PRSP with MIC range of 0.05-3.13 /ig/ml and was superior to CFDN, but inferior to CDTR.Strains ofH. influenzae resistant to benzylpenicillin were highly susceptible to FK041, which was more active than CFDN, but less active than CDTR. Against fluoroquinolone-resistant E. coli, K. pneumoniae, and P. mirabilis, FK041 had an excellent activity, superior to those of CFDN and CDTR,and there was no cross resistance with LVFX. 
Comparison of Broth Dilution MBCsand MICs ofFK041
The microdilution broth MBCsand MICs of FK041 and the reference compoundsagainst 8 to 10 strains each are shown in Table 5 . The mean MBCsofFK041 were similar to the mean MICs against all organisms tested. The mean MBCsofFK041 against the organisms ranged from 0.10 to 0.20jUg/ml and were superior to those of CFDNand CDTR, except that it was inferior to CDTRin terms of MBCagainst H. influenzae.
Stability of FK041 to /3-Lactamases Hydrolysis
Relative Vmax/Krnvalues of FK041for various j8-lactamases were compared with those of CFDNand CDTR (Table 6 ). Based on these values, FK041 was highly stable to group 2a and 2b B-lactamase hydrolysis but was unstable JULY 1999 to group lb and lc /3-lactamase hydrolysis. The stability of FK041to these enzymes was similar to those ofCFDNand CDTR. FK041 exhibited good activity against group 2a and 2b /3-lactamase-producing strains, but was inactive against group lb /3-lactamase-producing E. coli, reflecting its stability to these enzymes. Concentrations (/ig/ml) of drug required to reduce C-benzylpenicillin binding by 50%.
PBPs and its high stability to jS-lactamases. antibiotics18 '19) . FK041 showed moderate activity against PRSP, with an MIC90 of 3.13 /ig/ml, but the activity against PRSP was decreased by 16Tfold in comparison with that against PSSP Resistance to penicillin G is due to the development of altered forms of some of the PBPs, which thereby have decreased affinity for the antibiotic20~23).
Increase in the MICof FK041 against PRSPseems to be due to a decrease in affinity for PBPs 1A and 2X, which JULY 1999 have shownto be associated with resistance to cephem antibiotics20 
